Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADES-2: KITE-753 vs axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma after first-line therapy
jRCT2073260075Phase 3Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
Phase 3, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing KITE-753 arm with Axicabtagene ciloleucel arm (2 arms). Primary endpoints: Six-month complete remission (CR) rate and Event-free survival (EFS). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
KITE-753axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2073260075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073260075.